Braun Stacey Associates Inc. Cuts Stock Position in Boston Scientific Co. (NYSE:BSX)

Braun Stacey Associates Inc. trimmed its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 267,743 shares of the medical equipment provider’s stock after selling 3,513 shares during the period. Braun Stacey Associates Inc.’s holdings in Boston Scientific were worth $23,915,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Creative Planning grew its stake in shares of Boston Scientific by 7.7% in the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock valued at $17,113,000 after buying an additional 14,663 shares in the last quarter. Global Retirement Partners LLC boosted its holdings in Boston Scientific by 11.5% in the 3rd quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider’s stock worth $366,000 after acquiring an additional 449 shares during the period. Stratos Wealth Advisors LLC grew its position in Boston Scientific by 8.9% in the third quarter. Stratos Wealth Advisors LLC now owns 6,419 shares of the medical equipment provider’s stock valued at $538,000 after acquiring an additional 522 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Boston Scientific by 91.6% during the third quarter. Blue Trust Inc. now owns 10,492 shares of the medical equipment provider’s stock valued at $808,000 after purchasing an additional 5,017 shares during the period. Finally, Capital Investment Advisors LLC acquired a new position in shares of Boston Scientific during the third quarter worth $217,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on BSX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a report on Thursday, February 6th. TD Cowen lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, December 12th. Stifel Nicolaus boosted their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. StockNews.com upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. Finally, Raymond James upped their target price on Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a research report on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Boston Scientific currently has a consensus rating of “Buy” and an average price target of $107.39.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares of the company’s stock, valued at $560,103.60. This represents a 75.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Daniel J. Brennan sold 15,087 shares of Boston Scientific stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the sale, the chief financial officer now directly owns 241,451 shares in the company, valued at $25,369,256.57. The trade was a 5.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 87,326 shares of company stock valued at $8,673,948 in the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.1 %

NYSE:BSX opened at $106.20 on Tuesday. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average of $96.44 and a 200-day moving average of $88.39. The firm has a market capitalization of $156.51 billion, a PE ratio of 84.96, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 52 week low of $65.33 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Analysts predict that Boston Scientific Co. will post 2.83 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.